Trial · NCT07903688
Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance
NCT07903688, Not applicable, Not yet recruiting, Beth Israel Deaconess Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance. Trials, record NCT07903688. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903688
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance
- NCT number
- NCT07903688
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Conditions
- Healthy
- Interventions
- Nadi Shuddhi, Shoonya Meditation
- First posted
- 2026-10-29
- Last updated
- 2026-11-10
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Acquisition of physiological data using the GLYMPHOMETER during meditation and yogic breathing sessions. | At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2 | Participants meeting threshold for analyzable device recordings. |
| Secondary | Neurofluid-related physiological measures during Shoonya meditation and Nadi Shuddhi breathing. | At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2 | Changes in GLYMPHOMETER-derived measures of neurofluid coupling, during Shoonya meditation and Nadi Shuddhi breathing. (Measurement device: Glymphometer; Measure: Neurofluid coupling aka Fluid dynamics in brain) |
| Secondary | Autonomic regulation during Shoonya meditation and Nadi Shuddhi breathing. | At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2 | Changes in heart-rate variability (HRV) during Shoonya meditation and Nadi Shuddhi breathing. |
| Secondary | Very-low-frequency physiological signal characteristics | At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2 | Changes in predefined very-low-frequency (0.001-0.1 Hz) signal characteristics derived from GLYMPHOMETER medical™ recordings and their relationship to neurofluid-related measures. |
| Other | Differences in neurophysiological responses according to meditation experience. | From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment. | Comparison of changes in GLYMPHOMETER-derived measures of neurofluid coupling between novice and advanced meditators. |
| Other | Mindful Attention Awareness Scale | Once at Baseline. Estimated acquisition window: 5-8 minutes | We assess for change in Mindfulness levels by using a validated scale for this purpose namely, Mindfulness Attention Awareness Scale (MAAS). The scale measures the individuals' ability for receptive awareness and attention to present. This aids in evaluating any change on the individual's awareness levels after the Inner engineering intervention. We compute the MAAS scores for each participant which is a mean score for 15 item questionnaires and compare the pre \& post intervention results to look for change. Participants are asked to rate on a scale of 1 (Almost Always) to 6 (Almost Never) to assess the frequency of occurrence of each experience. Mean is then computed using items from each of the 15 questions to create a MAAS score, ranging from 0 to 6. Higher MAAS scores indicate better mindfulness state. |
| Other | Meditation Depth Questionnaires | At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2 | This 30-item measure assesses the subjective depth of meditation across progressively deeper experiential states. Items are typically rated on a 5-point Likert scale and are grouped into five empirically derived domains: hindrances, relaxation, personal-self/concentration, essential/transpersonal qualities, and transpersonal-self/non-duality. Together, these domains capture experiences ranging from obstacles and relaxation during meditation to focused concentration, transpersonal qualities, and experiences of diminished self-boundaries or non-dual awareness. |
| Other | Correlation between GLYMPHOMETER-derived neurofluid metrics and MRI-based neurofluid dynamics (Validation of Portable Device). | From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment. | This outcome evaluates the concurrent validity of the portable device against the gold standard. The statistical method will be a correlation analysis (Pearson or Spearman, as appropriate based on data distribution). * Measurement 1 (Variable A): Neurofluid coupling oscillations measured via the GLYMPHOMETER medical™ device (measured as relative changes in HbO, HbR, HbT, and CSF/H2O proportional signal including interhemispheric correlation coefficient across these neurofluid compartments while gating each of them to very low frequency, respiratory and cardiac frequency bands). * Measurement 2 (Variable B): Global neurofluid dynamics and CSF flow measured via 3T MRI using fast fMRI and phase-contrast sequences (measured as BOLD-CSF coupling magnitude and CSF stroke volume in mL). * Assessment: The study will assess the correlation between the magnitude of oscillatory coupling in Measurement 1 with the absolute flow dynamics in Measurement 2 during the designated validation windows. |
| Other | Correlation between GLYMPHOMETER-derived neurofluid metrics and plasma brain-derived biomarkers. | From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment. | This outcome evaluates the relationship between neurofluid dynamics and blood-based markers of brain clearance. The statistical method will be a correlation analysis (Pearson or Spearman). * Measurement 1 (Variable A): Neurofluid coupling oscillations measured via the GLYMPHOMETER medical™ device (measured as relative changes in HbO, HbR, HbT, and CSF/H2O proportional signal including interhemispheric correlation coefficient across these neurofluidic compartments while gating each of them to very low frequency, respiratory and cardiac frequency bands). * Measurement 2 (Variable B): Plasma concentrations of brain-derived proteins/peptides (Aβ40, Aβ42, total/phosphorylated tau, NF-L, GFAP) measured via ultra-sensitive Simoa immunoassay (measured in pg/mL). * Assessment: The study will assess the correlation between acute GLYMPHOMETER-derived neurofluid changes and plasma biomarker concentrations before and after intervention. |
| Other | Qualitative assessment of meditation and breathing experiences. | At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2 | Qualitative characterization of participant experiences using one-on-one micro-phenomenological interviews. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903688
GET https://conductscience.org/api/trials/v1/NCT07903688/registered